Tiazofurin enhances the anabolism and toxicity of 5-fluorouracil

被引:0
作者
Cysyk, RL [1 ]
Chisena, CA [1 ]
Hyman, R [1 ]
Monks, A [1 ]
机构
[1] NCI,FREDERICK CANC RES & DEV CTR,SAIC FREDERICK,FREDERICK,MD
关键词
tiazofurin; 5-fluorouracil; 5-phosphoribosyl-1-pyrophosphate (PRPP); pyrimidines;
D O I
10.1016/S0304-3835(96)04416-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tiazofurin, a clinically active anticancer agent, is undergoing additional clinical testing in combination with other agents. We found that tiazofurin is an effective biochemical modulator of 5-fluorouracil anabolism. Pretreatment of cultured L1210 cells with tiazofurin at concentrations of 1-100 mu M results in an increase in the rate of conversion of 5-fluorouracil to phosphorylated metabolites. Concentrations of tiazofurin effective in increasing 5-fluorouracil anabolism cause a corresponding increase in the 5-phosphoribosyl-1-pyrophosphate pool. Studies in mice show that tiazofurin increases the lethal toxicity of 5-fluorouracil and increases the antitumor effectiveness of low doses of 5-fluorouracil; however, the combination is not more effective than an optimal dose of 5-fluorouracil given alone. These results indicate that caution should be exercised in the concurrent use of tiazofurin with other drugs, particularly 5-fluorouracil, that require 5-phosphoribosyl-1-pyrophosphate for activation or that are affected by a decrease in pyrimidine nucleotide synthesis.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 50 条
  • [41] Niosomal delivery of 5-fluorouracil
    Namdeo, A
    Jain, NK
    JOURNAL OF MICROENCAPSULATION, 1999, 16 (06) : 731 - 740
  • [42] 5-Fluorouracil and dihydropyrimidine dehydrogenase
    Tetsuro Kubota
    International Journal of Clinical Oncology, 2003, 8 (3) : 127 - 131
  • [43] How 5-fluorouracil acts
    Wawrocka-Pawlak, Marlena
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2005, 9 (10): : 414 - 423
  • [44] Autoregulation of 5-fluorouracil metabolism
    McLeod, HL
    Sludden, J
    Hardy, SC
    Lock, RE
    Hawksworth, GM
    Cassidy, J
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) : 1623 - 1627
  • [45] Adjuvant chemotherapy with 5-fluorouracil and folinic acid in colorectal cancer: Evaluation of toxicity
    Hartung, G
    Queisser, W
    Diezler, P
    Hagmuller, E
    Edler, L
    Jacob, I
    Wojatschek, C
    Seifert, A
    Weiss, H
    Weh, HJ
    Hoffknecht, M
    Clemens, MR
    Fritze, D
    Katz, R
    Harle, M
    ONKOLOGIE, 1996, 19 (01): : 62 - 67
  • [46] Therapeutic effect of berberine against 5-fluorouracil induced ovarian toxicity in rats
    Demir, Selim
    Alemdar, Nihal Turkmen
    Kucuk, Hatice
    Demir, Elif Ayazoglu
    Mentese, Ahmet
    Aliyazicioglu, Yuksel
    BIOTECHNIC & HISTOCHEMISTRY, 2024, 99 (07) : 379 - 385
  • [47] Pharmacology of Perioperative 5-Fluorouracil
    Van der Speeten, K.
    Stuart, O. A.
    Mahteme, H.
    Sugarbaker, Paul H.
    JOURNAL OF SURGICAL ONCOLOGY, 2010, 102 (07) : 730 - 735
  • [48] Polymeric prodrugs of 5-fluorouracil
    Nichifor, M
    Schacht, EH
    Seymour, LW
    JOURNAL OF CONTROLLED RELEASE, 1997, 48 (2-3) : 165 - 178
  • [49] 5-fluorouracil and cardiotoxicity: a review
    Sara, Jaskanwal D.
    Kaur, Jasvinder
    Khodadadi, Ryan
    Rehman, Muneeb
    Lobo, Ronstan
    Chakrabarti, Sakti
    Herrmann, Joerg
    Lerman, Amir
    Grothey, Axel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [50] Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio
    Sistonen, Johanna
    Buechel, Barbara
    Froehlich, Tanja K.
    Kummer, Dominic
    Fontana, Stefano
    Joerger, Markus
    van Kuilenburg, Andre B. P.
    Largiader, Carlo R.
    PHARMACOGENOMICS, 2014, 15 (13) : 1653 - 1666